Novel therapies for the management of type 2 diabetes mellitus: Part 2. Addressing the incretin defect in the clinical setting in 2013

Journal of Diabetes

Volumn 5, Issue 3, 2013, Pages 241-253

  Grunberger, George ^a  

^a Grunberger Diabetes Institute   (United States)

Author keywords

Antidiabetic drugs; Dipeptidyl peptidase 4 inhibitors; Glucagon like peptide 1 receptor agonists; Incretin analogs; Type 2 diabetes therapy

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIMEPIRIDE; GLIMEPIRIDE PLUS METFORMIN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HEMOGLOBIN A1C; INCRETIN; INSULIN; INSULIN GLARGINE; LINAGLIPTIN; LIRAGLUTIDE; METFORMIN; METFORMIN PLUS SITAGLIPTIN; PIOGLITAZONE; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; VILDAGLIPTIN;

CLINICAL PRACTICE; DIARRHEA; DRUG STRUCTURE; DRUG TARGETING; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; LIFESTYLE MODIFICATION; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; VOMITING;

ANTIDIABETIC DRUGS; DIPEPTIDYL PEPTIDASE 4 INHIBITORS; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS; INCRETIN ANALOGS; TYPE 2 DIABETES THERAPY;

DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; MOLECULAR STRUCTURE; PEPTIDES; PYRAZINES; RECEPTORS, GLUCAGON; TREATMENT OUTCOME; TRIAZOLES; VENOMS;

EID: 84881543697     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/1753-0407.12046     Document Type: Review

References (87)

1. Elrick H, Stimmler L, Hlad CJ etal. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab. 1964; 24: 1076-1082.
2. Moore B, Edie ES, Abram JH. Further observations on the treatment of diabetes mellitus by acid extract of duodenal mucous membrane. Biochem J. 1906; 1: 446-454.
3. La Barre J. Sur les possibilities d'un traitement du diabète par l'incrétine. Bull Acad R Med Belg. 1932; 12: 620-634.
4. Nauck M, Stöckmann F, Ebert R etal. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986; 29: 46-52.
5. Nauck MA, Homberger S, Siegel EG etal. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab. 1986; 63: 492-498.
6. 2-terminus in type II diabetic patients and in healthy subjects. Diabetes. 1995; 44: 1126-1131.
7. Nauck MA, Heimesaat MM, Behle K etal. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive function, and insulin secretion during hyperinsulinemic, stepped hypoglycemic lamp experiments in healthy volunteers. J Clin Endocrinol Metab. 2002; 87: 1239-1246.
8. Meier JJ, Nauck MA. Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function? Diabetes. 2010; 59: 1117-1125.
9. Vilsbøll T, Krarup T, Madsbad S, Holst JJ. Defective amplification of the late phase insulin response to glucose by GIP in obese type II diabetic patients. Diabetologia. 2002; 45: 1111-1119.
10. Nauck MA, Heimesaat MM, Ørskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type 2 diabetes mellitus. J Clin Invest. 1993; 91: 301-307.
11. Højberg PV, Vilsbøll T, Rabøl R etal. Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia. 2009; 52: 199-207.
12. Agersø H, Jensen LB, Elbrønd B etal. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, anew long-acting GLP-1 derivative, in healthy men. Diabetologia. 2002; 45: 195-202.
13. Herman GA, Bergman A, Stevens C etal. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab. 2006; 91: 4612-4619.
14. Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care. 2003; 26: 2929-2940.
15. Raz I, Hanefeld M, Xu L etal. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes mellitus. Diabetologia. 2006; 49: 2564-2571.
16. Aschner P, Kipnes MS, Lunceford JK etal. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006; 29: 2632-2637.
17. Goldstein B, Feinglos MN, Lunceford JK etal. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes [published erratum appears in Diabetes Care. 2008;31:1713]. Diabetes Care. 2007; 30: 1979-1987.
18. Rosenstock J, Aguilar-Salinas C, KLein E etal. Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes. Curr Med Res Opin. 2009; 25: 2401-2411.
19. Dejager S, Schweizer A, Foley JE. Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus. Vasc Health Risk Manag. 2012; 8: 339-348.
20. Del Prato S, Barnett AH, Huisman H etal. Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: A randomized controlled trial. Diabetes Obes Metab. 2011; 13: 258-267.
21. Gomis R, Owens DR, Taskinen MR etal. Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: Up to 2 years exposure in 24-week Phase III trials followed by a 78-week open-label extension. Int J Clin Pract. 2012; 66: 731-740.
22. DeFronzo RA, Fleck PR, Wilson CA, Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: A randomized, double-blind, placebo-controlled study. Diabetes Care. 2008; 31: 2315-2317.
23. Williams-Herman D, Johnson J, Teng R etal. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over two years in patients with type 2 diabetes. Diabetes Obes Metab. 2010; 12: 442-451.
24. Rosenstock J, Brazg R, Andryuk PJ etal. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy on patients with type 2 diabetes: A 24-week multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2006; 28: 1556-1568.
25. Charbonnel B, Karasik A, Liu J etal. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006; 29: 2638-2643.
26. Hermansen K, Kipnes M, Luo E etal. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab. 2007; 9: 733-745.
27. Vilsbøll T, Rosenstock J, Yki-Järvinen H etal. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2012; 12: 167-177.
28. Hong ES, Khang AR, Yoon JW etal. Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study. Diabetes Obes Metab. 2012; 14: 795-802.
29. DeFronzo RA, Hissa MN, Garber AJ etal. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care. 2009; 32: 1649-1655.
30. Chacra AR, Tan GH, Apanovitch A etal. Saxagliptin added to submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: A randomised controlled trial. Int J Clin Pract. 2009; 63: 1395-1406.
31. Hollander P, Li J, Allen E etal. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab. 2009; 94: 4810-4819.
32. Barnett AH, Charbonnel B, Donovan M, Fleming D, Chen R. Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. Curr Med Res Opin. 2012; 28: 513-523.
33. Forst T, Uhlig-Laske B, Ring A etal. Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled type 2 diabetes. Diabet Med. 2010; 27: 1409-1419.
34. Taskinen MR, Rosenstock J, Tamminen I etal. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2011; 13: 65-74.
35. Owens DR, Swallow R, Dugi KA, Woerle HJ. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: A 24-week randomized study. Diabet Med. 2011; 28: 1352-1361.
36. Gomis R, Espadero R-M, Jones R, Woerle HJ, Dugi KA. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: A randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2011; 13: 653-661.
37. Yki-Järvinen H, Duran-Garcia S, Pinnetti S etal. Efficacy and safety of linagliptin as add-on therapy to basal insulin in patients with type 2 diabetes. Diabetes. 2012; 61 (Suppl. 1): A255. (Abstract).
38. Blech S, Ludwig-Schwellinger E, Grafe-Mody EU, Withopf B, Wagner K. The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. Drug Metab Dispos. 2010; 38: 667-678.
39. Graefe-Mody U, Friedrich C, Port A etal. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes Metab. 2011; 13: 939-946.
40. Graefe-Mody U, Giessmann T, Ring A, Iovino M, Woerle HJ. A randomized, open-label, crossover study evaluating the effect of food on the relative bioavailability of linagliptin in healthy subjects. Clin Ther. 2011; 33: 1096-1103.
41. Ahrén B, Gomis R, Standl E, Mills D, Schweizer A. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care. 2004; 27: 2874-2880.
42. Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care. 2007; 30: 890-895.
43. Rosenstock J, Kim SW, Baron MA etal. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab. 2007; 9: 175-185.
44. Garber AJ, Schweizer A, Baron MA, Rochotte E, Dejager S. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: A randomized, placebo-controlled study. Diabetes Obes Metab. 2007; 9: 166-174.
45. Fonseca V, Schweizer A, Albrecht D, Baron MA, Chang I, Dejager S. Addition of vildagliptin to insulin improves glycemic control in type 2 diabetes. Diabetologia. 2007; 50: 1148-1155.
46. DeFronzo RA, Burant CF, Fleck P, Wilson C, Mekki Q, Pratley RE. Effect of alogliptin combined with pioglitazone in glycemic control in metformin-treated patients with type 2 diabetes. J Clin Endocrinol Metab. 2012; 97: 1615-1622.
47. Rosenstock J, Rendell MS, Gross JL, Fleck PR, Wilson CA, Mekki Q. Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia. Diabetes Obes Metab. 2009; 11: 1145-1152.
48. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. J Biol Chem. 1992; 267: 7402-7405.
49. Thorens B, Porret A, Buhler L, Deng SP, Morel P, Widmann C. Cloning and functional expression of the human islet GLKP-1 receptor. Demonstration that exendin-4 is an agonist and exendin (9-39) an antagonist of the receptor. Diabetes. 1993; 42: 1678-1682.
50. Nelson P, Poon T, Guan X, Schnabel C, Wintle M, Fineman M. The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes. Diabetes Technol Ther. 2007; 9: 317-326.
51. Moretto TJ, Milton DR, Ridge TD etal. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2008; 30: 1448-1460.
52. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004; 27: 2628-2635.
53. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005; 28: 1092-1100.
54. Kendall DM, Riddle MC, Rosenstock J etal. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005; 28: 1083-1091.
55. Derosa G, Maffioli P, Salvadeo SA etal. Exenatide versus glibenclamide in patients with diabetes. Diabetes Technol Ther. 2010; 12: 233-240.
56. Zinman B, Hoogwerf BJ, Durán García S etal. Effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: A randomized trial. Ann Intern Med. 2007; 146: 477-485.
57. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: A randomized trial. Ann Intern Med. 2005; 143: 559-569.
58. Barnett AH, Burger J, Johns D etal. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: A multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther. 2007; 29: 2333-2348.
59. Nauck MA, Duran S, Kim D etal. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: A non-inferiority study. Diabetologia. 2007; 50: 259-267.
60. Buse JB, Bergenstal RM, Glass LC etal. Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: A randomized, controlled trial. Ann Intern Med. 2011; 154: 103-112.
61. Violante R, Oliveira JH, Yoon KH etal. A randomized non-inferiority study comparing the addition of exenatide twice daily to sitagliptin or switching from sitagliptin to exenatide twice daily in patients with type 2 diabetes experiencing inadequate glycaemic control on metformin and sitagliptin. Diabet Med. 2012; 29: e417-424.
62. Drucker DJ, Buse JB, Taylor K etal. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: A randomised, open-label, non-inferiority study. Lancet. 2008; 372: 1240-1250.
63. Buse JB, Drucker DJ, Taylor KL etal. Exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care. 2010; 33: 1255-1261.
64. Bergenstal RM, Wysham C, Macconell L etal. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): A randomised trial. Lancet. 2010; 376: 431-439.
65. Diamant M, Van Gaal L, Stranks S etal. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): An open-label randomised trial. Lancet. 2010; 375: 2234-2243.
66. Russell-Jones D, Cuddihy RM, Hanefeld M etal. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): A 26-week double-blind study. Diabetes Care. 2012; 35: 252-258.
67. Blevins T, Pullman J, Malloy J etal. DURATION-5: Exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011; 96: 1301-1310.
68. Buse JB, Nauck M, Forst T etal. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): A randomised, open-label study. Lancet. 2013; 381: 117-124.
69. Marre M, Shaw J, Brändle M etal. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med. 2009; 26: 268-278.
70. Nauck M, Frid A, Hermansen K etal. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: The LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009; 32: 84-90.
71. Garber A, Henry R, Ratner R etal. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): A randomised, 52-week, Phase III, double-blind, parallel-treatment trial. Lancet. 2009; 373: 473-481.
72. Zinman B, Gerich J, Buse JB etal. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD) [published erratum appears in Diabetes Care. 2010; 33(3): 692]. Diabetes Care. 2009; 32: 1224-1230.
73. Russell-Jones D, Vaag A, Schmitz O etal. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): A randomised controlled trial. Diabetologia. 2009; 52: 2046-2055.
74. Buse JB, Rosenstock J, Sesti G etal. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: A 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009; 374: 39-47.
75. Buse JB, Sesti G, Schmidt WE etal. Switching to once-daly liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes Care. 2010; 33: 1300-1303.
76. Mari A, Sallas WM, He YL etal. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab. 2005; 90: 4888-4894.
77. Ahren B. Vildagliptin: An inhibitor of dipeptidyl peptidase-4 with antidiabetic properties. Expert Opin Investig Drugs. 2006; 15: 431-442.
78. Degn KB, Juhl CB, Sturis J etal. One week's treatment with the long-acting glucagon-like peptide derivative liraglutide (NN2211) markedly improves 24-h glycemia an α- and β-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes. 2004; 53: 1187-1194.
79. El-Ouaghlidi A, Rehring E, Holst JJ etal. The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion. J Clin Endocrinol Metab. 2007; 92: 4165-4171.
80. Deacon CF, Wamberg S, Bie P, Hughes TE, Holst JJ. Preservation of active incretin hormones by inhibition of dipeptidyl peptidase-IV suppresses meal-induced incretin secretion in dogs. J Clin Endcorinol. 2002; 172: 355-362.
81. Nauck MA. Incretin-based therapies for type 2 diabetes mellitus: Properties, functions and clinical implications. Am J Med. 2011; 124 (Suppl.) S3-18.
82. Gooßen K, Gräber S. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: Systematic review and meta-analysis. Diabetes Obes Metab. 2012; 14: 1061-1072.
83. Bloomgarden Z. Diabetes treatment: The coming paradigm shift. J Diabetes. 2012; 4: 315-317.
84. Cobble ME, Frederich R. Saxagliptin for the treatment of type 2 diabetes mellitus: Assessing cardiovascular data. Cardiovasc Diabetol. 2012; 11: 6.
85. Drucker DJ, Sherman SI, Bergenstal RM, Buse JB. The safety of incretin-based therapies: Review of the scientific evidence. J Clin Endocrinol Metab. 2011; 96: 2027-2031.
86. Butler PC, Dry S, Elashoff R. GLP-1-based therapy for diabetes: What you do not know can hurt you. Diabetes Care. 2010; 33: 453-455.
87. Mudaliar S, Henry RR. The incretin hormones: From scientific discovery to practical therapeutics. Diabetologia. 2012; 55: 1865-1868.